177 related articles for article (PubMed ID: 27774665)
1. Potential inhibition of development of rapidly progressive interstitial lung disease by prompt and sufficient immunosuppressive treatment in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Shu E; Kanoh H; Murakami A; Seishima M
J Dermatol; 2017 May; 44(5):e91-e92. PubMed ID: 27774665
[No Abstract] [Full Text] [Related]
2. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis.
Hisanaga J; Kotani T; Fujiki Y; Yoshida S; Takeuchi T; Makino S
Int J Rheum Dis; 2017 Dec; 20(12):2182-2185. PubMed ID: 28752606
[No Abstract] [Full Text] [Related]
3. The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level.
Osawa T; Morimoto K; Sasaki Y; Matsuda S; Yamana K; Yano R; Uchiyama T; Goto H
Intern Med; 2018 Feb; 57(3):387-391. PubMed ID: 29093381
[TBL] [Abstract][Full Text] [Related]
4. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for refractory rapidly progressive interstitial lung disease related to anti-MDA5-positive dermatomyositis.
Zhang X; Zhou S; Wu C; Li M; Wang Q; Zhao Y; Zeng X
Rheumatology (Oxford); 2021 Jul; 60(7):e227-e228. PubMed ID: 33410494
[No Abstract] [Full Text] [Related]
6. Perspectives in the treatment of interstitial lung disease accompanied with anti-melanoma differentiation-associated gene 5-positive dermatomyositis.
Tsuji H; Nakashima R; Mimori T
Int J Rheum Dis; 2024 May; 27(5):e15201. PubMed ID: 38769940
[No Abstract] [Full Text] [Related]
7. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
8. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
9. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
10. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis.
Tsuji H; Nakashima R; Hosono Y; Imura Y; Yagita M; Yoshifuji H; Hirata S; Nojima T; Sugiyama E; Hatta K; Taguchi Y; Katayama M; Tanizawa K; Handa T; Uozumi R; Akizuki S; Murakami K; Hashimoto M; Tanaka M; Ohmura K; Mimori T
Arthritis Rheumatol; 2020 Mar; 72(3):488-498. PubMed ID: 31524333
[TBL] [Abstract][Full Text] [Related]
11. A case of anti-MDA5 antibody-positive dermatomyositis developing reversible cerebral vasospasm syndrome successfully treated by multi-immunosuppressant combination including mycophenolate mofetil.
Muramatsu T; Tono T; Kanayama Y; Hasegawa Y; Kondo J; Hoshiyama T; Wada T; Arinuma Y; Tanaka S; Yamaoka K
Mod Rheumatol Case Rep; 2021 Jan; 5(1):69-75. PubMed ID: 32811369
[TBL] [Abstract][Full Text] [Related]
12. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
[TBL] [Abstract][Full Text] [Related]
13. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
Nandy A; Gaïni S; Sore P
Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
[No Abstract] [Full Text] [Related]
14. Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant.
Chan CWS; Chung HY; Lau CS; Tsang HHL
Int J Rheum Dis; 2019 Mar; 22(3):521-524. PubMed ID: 28580698
[TBL] [Abstract][Full Text] [Related]
15. Anti-MDA5 Antibody-positive Dermatomyositis Complicated by Autoimmune-associated Hemophagocytic Syndrome That Was Successfully Treated with Immunosuppressive Therapy and Plasmapheresis.
Fujita Y; Fukui S; Suzuki T; Ishida M; Endo Y; Tsuji S; Takatani A; Igawa T; Shimizu T; Umeda M; Sumiyoshi R; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Abe K; Kawakami A
Intern Med; 2018 Dec; 57(23):3473-3478. PubMed ID: 29984753
[TBL] [Abstract][Full Text] [Related]
16. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
[TBL] [Abstract][Full Text] [Related]
17. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.
Ohmura SI; Yamabe T; Naniwa T
Mod Rheumatol Case Rep; 2021 Jan; 5(1):76-81. PubMed ID: 32867615
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of multi-target therapy in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with early-stage interstitial lung disease.
Suda M; Kataoka Y; Tomishima Y; Jinta T; Rokutanda R; Kishimoto M; Okada M
Scand J Rheumatol; 2017 Nov; 46(6):505-506. PubMed ID: 28649889
[No Abstract] [Full Text] [Related]
19. A Case of Dermatomyositis with Severe Myalgia and Muscle Weakness Testing Positive for Anti-melanoma Differentiation-associated Gene 5 Antibody.
Yamazaki K; Wakabayashi H; Suganami Y; Sano S; Wakunami Y; Katayama T; Deguchi K; Nagotani S; Kishida M
Acta Med Okayama; 2017 Aug; 71(4):341-344. PubMed ID: 28824190
[TBL] [Abstract][Full Text] [Related]
20. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
